Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Ammonia Solution, Strong. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL8549003 | 1.00 | — | — | |
| Ammonia Solution, Strong SCHEMBL524152 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL9763208 | 0.92 | — | — | |
| SCHEMBL45362 | 0.92 | — | — | |
| SCHEMBL12111341 | 0.92 | — | — | |
| SCHEMBL12111337 | 0.92 | — | — | |
| SCHEMBL27702029 | 0.88 | — | — | |
| SCHEMBL27769735 | 0.88 | — | — | |
| SCHEMBL27348093 | 0.88 | — | — | |
| Phosphine SCHEMBL28154723 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406227-A1 | PROCESS FOR MANUFACTURING 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY) HEXYL]AMINO}-1- HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE. | Almirall S.A. (ES) | 2012-01-18 | — | — | EP | claimed |
| WO-2010102831-A1 | PROCESS FOR MANUFACTURING 5-(2-{[6-(2,2-DIFLUORO-2-PHENYIETHOXY) HEXYL]AMINO}-L- HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE. | ALMIRALL, S.A. (ES) | 2010-09-16 | — | — | WO | claimed |
| US-10669538-B2 | Templated molecules and methods for using such molecules | NUEVOLUTION A/S (DK) | 2020-06-02 | — | — | US | disclosed |
| US-20170198283-A1 | TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES | NUEVOLUTION A/S (DK) | 2017-07-13 | — | — | US | disclosed |
| EP-3010591-B1 | CATIONIC GROUP-CONTAINING CELLULOSE ETHER | KAO CORP (JP) | 2017-04-12 | — | — | EP | disclosed |
| US-9456977-B2 | Cationized glycerolated cellulose | KAO CORPORATION (JP) | 2016-10-04 | — | — | US | disclosed |
| EP-3010591-A1 | CATIONIC GROUP-CONTAINING CELLULOSE ETHER | Kao Corporation (JP) | 2016-04-27 | — | — | EP | disclosed |
| US-20150064128-A1 | CATIONIZED GLYCEROLATED CELLULOSE | KAO CORPORATION (JP) | 2015-03-05 | — | — | US | disclosed |
| EP-2825263-A1 | CATIONISED GLYCEROLATED CELLULOSE | Kao Corporation (JP) | 2015-01-21 | — | — | EP | disclosed |
| US-8932992-B2 | Templated molecules and methods for using such molecules | NUEVOLUTION A/S (DK) | 2015-01-13 | — | — | US | disclosed |
| WO-2014203548-A1 | CATIONIC GROUP-CONTAINING CELLULOSE ETHER | KAO CORPORATION (JP) | 2014-12-24 | — | — | WO | disclosed |
| US-20100016177-A1 | TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES | NUEVOLUTION A/S (DK) | 2010-01-21 | — | — | US | disclosed |
| EP-1940775-A2 | METHODS AND COMPOSITIONS FOR THE EFFICIENT DELIVERY OF THERAPEUTIC AGENTS TO CELLS AND ANIMALS | University of Massachusetts (US) | 2008-07-09 | — | — | EP | disclosed |
| US-20070260055-A1 | Methods and compositions for the efficient delivery of therapeutic agents to cells and animals | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-08 | — | — | US | disclosed |
| WO-2007022030-A2 | METHODS AND COMPOSITIONS FOR THE EFFICIENT DELIVERY OF THERAPEUTIC AGENTS TO CELLS AND ANIMALS | UNIVERSITY OF MASSACHUSETTS (US) | 2007-02-22 | — | — | WO | disclosed |
| US-5952478-A | Intermediates for dinucleotide and oligonucleotide analogues | NOVARTIS FINANCE CORPORATION (US) | 1999-09-14 | — | — | US | disclosed |
| US-4665193-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1987-05-12 | — | — | US | disclosed |
| US-4629724-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1986-12-16 | — | — | US | disclosed |
| US-4616088-A | Amino acid ester and amide renin inhibitor | E. R. SQUIBB & SONS, INC. (US) | 1986-10-07 | — | — | US | disclosed |
| EP-0181071-A2 | Amino acid ester and amide renin inhibitors | E.R. Squibb & Sons, Inc. (US) | 1986-05-14 | — | — | EP | disclosed |